Published in Proc Natl Acad Sci U S A on June 25, 2008
ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res (2011) 14.51
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov (2009) 4.00
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A (2009) 2.80
Targeting Plasmodium PI(4)K to eliminate malaria. Nature (2013) 2.49
Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol (2009) 2.23
The systematic functional analysis of Plasmodium protein kinases identifies essential regulators of mosquito transmission. Cell Host Microbe (2010) 2.13
Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe (2012) 2.05
Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol (2013) 2.01
Identification of small molecule activators of cryptochrome. Science (2012) 1.95
Automated microscopy for high-content RNAi screening. J Cell Biol (2010) 1.87
A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development. Sci Rep (2011) 1.85
P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS One (2012) 1.80
Malaria research in the post-genomic era. Nature (2008) 1.78
Antimalarial drug discovery - approaches and progress towards new medicines. Nat Rev Microbiol (2013) 1.60
Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite. Proc Natl Acad Sci U S A (2012) 1.58
The global pipeline of new medicines for the control and elimination of malaria. Malar J (2012) 1.57
Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet (2013) 1.54
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol (2009) 1.52
Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol (2008) 1.52
A high-throughput screen targeting malaria transmission stages opens new avenues for drug development. J Infect Dis (2011) 1.49
Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model. J Biol Chem (2010) 1.46
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol (2012) 1.46
A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue. Mol Biochem Parasitol (2011) 1.43
Identification of inhibitors of Plasmodium falciparum gametocyte development. Malar J (2013) 1.43
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J Clin Microbiol (2010) 1.43
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay. Antimicrob Agents Chemother (2010) 1.42
Drug discovery: Priming the antimalarial pipeline. Nature (2010) 1.40
High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS Biol (2010) 1.38
Global phenotypic screening for antimalarials. Chem Biol (2012) 1.35
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. Proc Natl Acad Sci U S A (2012) 1.31
Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches. FASEB J (2011) 1.31
A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem Biol (2011) 1.31
Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening. Am J Trop Med Hyg (2012) 1.28
Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box. Antimicrob Agents Chemother (2013) 1.25
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. J Med Chem (2012) 1.22
Natural products as starting points for future anti-malarial therapies: going back to our roots? Malar J (2011) 1.22
Chemical signatures and new drug targets for gametocytocidal drug development. Sci Rep (2014) 1.22
Antimalarial drug discovery - the path towards eradication. Parasitology (2013) 1.19
An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS. ACS Med Chem Lett (2011) 1.18
Identification of MMV malaria box inhibitors of plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay. Antimicrob Agents Chemother (2013) 1.18
KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother (2014) 1.14
Solute restriction reveals an essential role for clag3-associated channels in malaria parasite nutrient acquisition. Mol Pharmacol (2012) 1.14
Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay. Antimicrob Agents Chemother (2009) 1.08
Target deconvolution techniques in modern phenotypic profiling. Curr Opin Chem Biol (2013) 1.08
A quantitative high throughput assay for identifying gametocytocidal compounds. Mol Biochem Parasitol (2013) 1.07
Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother (2012) 1.07
Using genetic methods to define the targets of compounds with antimalarial activity. J Med Chem (2013) 1.06
Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol Biochem Parasitol (2010) 1.06
Recent advances in malaria drug discovery. Bioorg Med Chem Lett (2013) 1.04
KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. Antimicrob Agents Chemother (2013) 1.03
Integrated dataset of screening hits against multiple neglected disease pathogens. PLoS Negl Trop Dis (2011) 1.03
Design and synthesis of inhibitors of Plasmodium falciparum N-myristoyltransferase, a promising target for antimalarial drug discovery. J Med Chem (2012) 1.03
Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. ACS Chem Biol (2014) 1.03
Synthesis and antimalarial activity of new 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas. Bioorg Med Chem (2008) 1.00
A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. J Med Chem (2011) 0.98
Changes in drug sensitivity and anti-malarial drug resistance mutations over time among Plasmodium falciparum parasites in Senegal. Malar J (2013) 0.98
Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Malar J (2013) 0.95
Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum. Malar J (2014) 0.94
Evaluation of bioluminescence-based assays of anti-malarial drug activity. Malar J (2013) 0.93
Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen. Antimicrob Agents Chemother (2011) 0.92
Identification of β-hematin inhibitors in a high-throughput screening effort reveals scaffolds with in vitro antimalarial activity. Int J Parasitol Drugs Drug Resist (2014) 0.92
High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission. Cell Host Microbe (2015) 0.92
Pan-Src family kinase inhibitors replace Sox2 during the direct reprogramming of somatic cells. Angew Chem Int Ed Engl (2011) 0.91
A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery. PLoS One (2015) 0.91
Imaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formation. Antimicrob Agents Chemother (2015) 0.91
Drugs for malaria: something old, something new, something borrowed. F1000 Biol Rep (2011) 0.91
Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo. Proc Natl Acad Sci U S A (2014) 0.91
Genomics and integrated systems biology in Plasmodium falciparum: a path to malaria control and eradication. Parasite Immunol (2012) 0.90
Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis. J Chem Inf Model (2014) 0.88
The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs. Int J Parasitol Drugs Drug Resist (2015) 0.88
Antiparasitic chemotherapy: from genomes to mechanisms. Annu Rev Pharmacol Toxicol (2013) 0.88
Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials. Curr Top Med Chem (2012) 0.88
Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay. Malar J (2015) 0.87
High-content live cell imaging with RNA probes: advancements in high-throughput antimalarial drug discovery. BMC Cell Biol (2009) 0.87
Salicylanilide inhibitors of Toxoplasma gondii. J Med Chem (2012) 0.87
Prediction of the P. falciparum target space relevant to malaria drug discovery. PLoS Comput Biol (2013) 0.87
A new in vivo screening paradigm to accelerate antimalarial drug discovery. PLoS One (2013) 0.86
Aminoindoles, a novel scaffold with potent activity against Plasmodium falciparum. Antimicrob Agents Chemother (2011) 0.86
Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS). ACS Med Chem Lett (2011) 0.86
Plasmodium falciparum NIMA-related kinase Pfnek-1: sex specificity and assessment of essentiality for the erythrocytic asexual cycle. Microbiology (2011) 0.86
Plasmodium IspD (2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target. ACS Infect Dis (2015) 0.85
Cell-based optimization of novel benzamides as potential antimalarial leads. Bioorg Med Chem Lett (2009) 0.85
A var gene promoter implicated in severe malaria nucleates silencing and is regulated by 3' untranslated region and intronic cis-elements. Int J Parasitol (2009) 0.85
A small molecule modulates circadian rhythms through phosphorylation of the period protein. Angew Chem Int Ed Engl (2011) 0.85
Phenotypic screens, chemical genomics, and antimalarial lead discovery. PLoS Pathog (2011) 0.84
The Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic Screens. PLoS Pathog (2017) 0.84
Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages. ACS Med Chem Lett (2014) 0.84
A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold. ACS Med Chem Lett (2012) 0.84
A broad analysis of resistance development in the malaria parasite. Nat Commun (2016) 0.84
Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease. PLoS Pathog (2015) 0.83
High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. ACS Infect Dis (2016) 0.81
A chemocentric approach to the identification of cancer targets. PLoS One (2012) 0.81
New insight-guided approaches to detect, cure, prevent and eliminate malaria. Protoplasma (2014) 0.81
Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites. J Med Chem (2014) 0.81
Identification of β-hematin inhibitors in the MMV Malaria Box. Int J Parasitol Drugs Drug Resist (2015) 0.81
Exploring the mode of action of bioactive compounds by microfluidic transcriptional profiling in mycobacteria. PLoS One (2013) 0.80
Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. ACS Cent Sci (2016) 0.80
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother (1979) 17.49
Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2006) 15.21
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother (2004) 7.51
Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet (1999) 5.06
Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev (2005) 4.04
Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob Agents Chemother (2004) 3.77
Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol (2003) 3.20
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother (2007) 3.08
A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. Am J Trop Med Hyg (2004) 2.87
A colorimetric in vitro drug sensitivity assay for Plasmodium falciparum based on a highly sensitive double-site lactate dehydrogenase antigen-capture enzyme-linked immunosorbent assay. Am J Trop Med Hyg (2001) 2.73
A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol (2006) 2.72
High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother (2006) 2.70
Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci U S A (2006) 2.43
Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des (2006) 2.10
Use of radioactive ethanolamine incorporation into phospholipids to assess in vitro antimalarial activity by the semiautomated microdilution technique. Antimicrob Agents Chemother (1992) 1.96
Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem Biol (2000) 1.75
Evidence-based annotation of the malaria parasite's genome using comparative expression profiling. PLoS One (2008) 1.61
Methionine recycling pathways and antimalarial drug design. Antimicrob Agents Chemother (1995) 1.40
Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors. Parasitology (2005) 1.35
In vitro and in vivo evaluation of betulinic acid as an antimalarial. Phytother Res (1999) 1.31
Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov Today (2003) 1.12
Novel statistical approach for primary high-throughput screening hit selection. J Chem Inf Model (2005) 1.08
Large-scale annotation of small-molecule libraries using public databases. J Chem Inf Model (2007) 1.08
Cytotoxicity and the inhibition of ribosomal RNA processing in human colon carcinoma cells. Mol Pharmacol (1985) 1.05
Evaluation of in vitro drug sensitivity of human Plasmodium falciparum by incorporation of radioactive isoleucine. J Med Assoc Thai (1975) 1.04
Folate metabolism as a source of molecular targets for antimalarials. Future Microbiol (2006) 1.01
Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr Med Chem (2003) 0.97
Knowledge-based chemoinformatic approaches to drug discovery. Drug Discov Today (2006) 0.96
Antimalarial properties of bredinin. Prediction based on identification of differences in human host-parasite purine metabolism. J Clin Invest (1982) 0.93
Calcium channel blockers inhibit cellular uptake of thymidine, uridine and leucine: the incorporation of these molecules into DNA, RNA and protein in the presence of calcium channel blockers is not a valid measure of lymphocyte activation. Immunopharmacology (1993) 0.91
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides. J Med Chem (1984) 0.90
Prolonged inhibition of protein and glycoprotein synthesis in tumor cells treated with muconomycin A. J Natl Cancer Inst (1977) 0.89
Inhibition of bovine and rat liver dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(4-substituted-phenyl)-s-triazines. J Med Chem (1981) 0.87
Functional profiling of the Saccharomyces cerevisiae genome. Nature (2002) 36.10
Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A (2002) 25.47
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Coordinated transcription of key pathways in the mouse by the circadian clock. Cell (2002) 14.07
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol (2009) 11.17
Discovery of gene function by expression profiling of the malaria parasite life cycle. Science (2003) 10.57
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol (2005) 9.25
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell (2008) 8.41
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature (2007) 7.12
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
Adding new chemistries to the genetic code. Annu Rev Biochem (2010) 6.32
Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol Biol Cell (2004) 6.04
Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci U S A (2002) 6.00
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A (2009) 5.86
Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science (2010) 5.50
Human host factors required for influenza virus replication. Nature (2010) 5.28
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Evidence that ternary complex (eIF2-GTP-tRNA(i)(Met))-deficient preinitiation complexes are core constituents of mammalian stress granules. Mol Biol Cell (2002) 5.20
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Mammalian stress granules and processing bodies. Methods Enzymol (2007) 4.76
An expanded eukaryotic genetic code. Science (2003) 4.66
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J (2004) 4.08
Angiogenin cleaves tRNA and promotes stress-induced translational repression. J Cell Biol (2009) 4.07
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A (2006) 3.83
Addition of a photocrosslinking amino acid to the genetic code of Escherichiacoli. Proc Natl Acad Sci U S A (2002) 3.77
Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle. Genome Res (2004) 3.63
Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat Methods (2007) 3.45
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Expanding the genetic code. Annu Rev Biophys Biomol Struct (2006) 3.36
A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods (2007) 3.34
A genome-wide RNAi screen for modifiers of the circadian clock in human cells. Cell (2009) 3.27
Angiogenin-induced tRNA fragments inhibit translation initiation. Mol Cell (2011) 3.23
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nat Chem Biol (2008) 3.23
A stem cell-based approach to cartilage repair. Science (2012) 3.22
An enhanced system for unnatural amino acid mutagenesis in E. coli. J Mol Biol (2009) 3.20
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A (2008) 3.13
Smartphone medication adherence apps: potential benefits to patients and providers. J Am Pharm Assoc (2003) (2013) 3.13
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
The Plasmodium falciparum sexual development transcriptome: a microarray analysis using ontology-based pattern identification. Mol Biochem Parasitol (2005) 3.02
ARE-mRNA degradation requires the 5'-3' decay pathway. EMBO Rep (2006) 3.01
Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol (2006) 2.96
A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog (2006) 2.92
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
Addition of p-azido-L-phenylalanine to the genetic code of Escherichia coli. J Am Chem Soc (2002) 2.88
Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure. J Biol Chem (2005) 2.85
Addition of the keto functional group to the genetic code of Escherichia coli. Proc Natl Acad Sci U S A (2002) 2.84
Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science (2005) 2.81
Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A (2009) 2.80
Expanding the genetic code. Angew Chem Int Ed Engl (2004) 2.78
A functional RNAi screen links O-GlcNAc modification of ribosomal proteins to stress granule and processing body assembly. Nat Cell Biol (2008) 2.76
Genomically recoded organisms expand biological functions. Science (2013) 2.73
mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science (2013) 2.71
In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol (2011) 2.69
Genetic diversity in yeast assessed with whole-genome oligonucleotide arrays. Genetics (2003) 2.68
Eukaryotic initiation factor 2alpha-independent pathway of stress granule induction by the natural product pateamine A. J Biol Chem (2006) 2.67
Self-renewal of embryonic stem cells by a small molecule. Proc Natl Acad Sci U S A (2006) 2.65
Angiogenin-induced tRNA-derived stress-induced RNAs promote stress-induced stress granule assembly. J Biol Chem (2010) 2.61
An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A (2006) 2.51